
Advance Agrolife IPO Price Range is ₹95 - ₹100, with a minimum investment of ₹15,000 for 150 shares per lot.
Subscription Rate
56.85x
as on 03 Oct 2025, 07:00PM IST
Minimum Investment
₹15,000
/ 150 shares
IPO Status
Price Band
₹95 - ₹100
Bidding Dates
Sep 30, 2025 - Oct 3, 2025
Issue Size
₹192.86 Cr
Lot Size
150 shares
Min Investment
₹15,000
Listing Exchange
BSE
IPO Doc




as on 03 Oct 2025, 07:00PM IST
IPO subscribed over
🚀 56.85x
This IPO has been subscribed by 23.058x in the retail category and 27.305x in the QIB category.
| Total Subscription | 56.85x |
| Retail Individual Investors | 23.058x |
| Qualified Institutional Buyers | 27.305x |
| Non Institutional Investors | 175.3x |
The company has shown steady growth over the last three fiscal years. Revenue increased at a CAGR of 12.4%, rising from ₹398 crores in FY23 to ₹502.9 crores in FY25, largely driven by higher domestic sales. Profit after tax (PAT) grew sharply between FY23 and FY24, jumping 66% to ₹24.7 crores due to improved operational efficiency and better supplier terms. In FY25, PAT edged up to ₹25.6 crores, while the PAT Margin slightly dipped to 5.1% because of higher operating costs, mainly from a 125% increase in depreciation linked to a new manufacturing facility.
The company expanded its asset base rapidly, with total assets rising at a 39.9% CAGR to ₹351.5 crores in FY25. This expansion was largely funded through debt, which surged at a 78.4% CAGR to ₹80.5 crores, raising the debt-to-equity ratio from 0.50 to 0.80 times. As a result, finance costs increased by 53.7%. EBITDA margins improved steadily from 6.3% in FY23 to 9.6% in FY25, reflecting better operational leverage despite rising costs.
Overall, the company has balanced growth with strategic investment in infrastructure, though rising debt and operating expenses may need close monitoring.
It operates an integrated production setup across three manufacturing facilities in Jaipur, Rajasthan, possessing a substantial annual installed capacity of 89,900 MTPA. This infrastructure allows production of both Technical and Formulation Grade products, granting high operational flexibility and opening new revenue streams.
The company has demonstrated consistent growth, achieving a revenue CAGR of 12.4% over the last two years, with FY25 revenue reaching ₹502.26 crore. Its profit after tax nearly doubled from ₹14.87 crore in FY23 to ₹25.64 crore in FY25.
It shows strong efficiency in converting capital into profits, indicated by a high Return on Net Worth (RoNW) of 29.11% and a Return on Capital Employed (ROCE) of 27.02% in FY25. These metrics demonstrate the company's efficient utilization of shareholder funds and total capital employed.
It maintains a strong and growing regulatory base, holding 410 generic registrations as of March 31, 2025, which includes 380 Formulation Grade and 30 Technical Grade products. This portfolio allows it to legally distribute products across 13 Indian states, enhancing market reach and stability.
The company benefits from long-standing B2B relationships with corporate customers, several of whom have been clients for periods ranging from 5 to over 9 years. This focus on quality and specific customer requirements ensures continuous revenue visibility and strengthens market presence through repeat orders.
Its Days Working Capital stood at 74 days in FY25, suggesting a faster conversion cycle compared to several large rivals. This is notably shorter than Insecticides India Limited (122 days) and PI Industries Limited (117 days).
The company faces a major risk from customer concentration, as its top 5 customers contributed ₹259.51 crore, representing 51.70% of total revenue in FY25. The loss of, or reduced revenue from, any of these key customers could materially and adversely affect its results.
The business is highly working capital intensive; net working capital rose to ₹100.34 crore in FY25. Projected working capital requirements are estimated to increase substantially to ₹306.76 crore by FY27, and failure to meet this large demand could hurt operations.
All manufacturing facilities are situated in Jaipur, Rajasthan, and a majority of its revenue (84% in FY25) is derived from key northern and central agricultural states. This geographic concentration exposes it to risks from adverse local factors, such as regional weather volatility or local regulatory changes.
Total borrowings have increased significantly, rising from ₹25.29 crore in FY23 to ₹80.45 crore in FY25. Consequently, the Debt-Equity Ratio has increased from 0.50 times to 0.80 times, indicating greater reliance on debt and higher interest obligations.
A significant amount of its trade receivables is concentrated in a single Group Company, HOK Agrichem Private Limited. The outstanding trade receivable balance owed by this entity reached ₹76.65 crore in FY25, up from ₹39.26 crore in FY24.
Company | Operating Revenue | EBITDA Margin | Profit | P/E Ratio | Return on Net Worth | Debt to Equity Ratio (x) | Days Working Capital |
Advance Agrolife | ₹502.3 Cr | 9.61% | ₹25.6 Cr | 25.07 | 29.11% | 0.8 | 74 |
₹951.0 Cr | 8.09% | ₹34.8 Cr | 34.6 | 9.24% | 0.29 | 73 | |
₹2,000.0 Cr | 11.41% | ₹142.0 Cr | 16.99 | 13.55% | 0.1 | 122 | |
₹1,409.7 Cr | 7.48% | ₹2.3 Cr | N/A | 0.37% | 0.41 | 48 | |
₹7,977.8 Cr | 31.63% | ₹1,660.2 Cr | 34.29 | 17.58% | 0.02 | 117 | |
₹4,319.9 Cr | 15.17% | ₹304.4 Cr | 30.33 | 12.85% | 0 | 113 |
| Promoters & Promoter Group | 99.84% | |
| Name | Role | Stakeholding |
| Om Prakash Choudhary | Promoter | 54.17% |
| Kedar Choudhary | Promoter | 36.05% |
| Geeta Choudhary | Promoter | 3.62% |
| Manisha Choudhary | Promoter | 3.28% |
| Kamla Devi Jat | Promoter Group | 2.72% |
| Others | Public | 0.16% |
Advance Agrolife IPO: GMP, Subscription, Strengths, Risks - Should You Apply?
Advance Agrolife IPO is open for subscription. Check GMP, subscription status, dates, business model, key risks, industry outlook, allotment details, and analyst view. In-depth research for informed investing.

The promoters of Advance Agrolife are Om Prakash Choudhary, Kedar Choudhary, Geeta Choudhary, and Manisha Choudhary. This group collectively held 43,706,000 Equity Shares, representing 97.12% of the company's pre-IPO equity share capital.
It operates in a competitive market against both domestic and international players. Key listed industry peers used for quantitative comparison are PI Industries Limited, Insecticides India Limited, Sharda Cropchem Limited, Dharmaj Crop Guard Limited, and Heranba Industries Limited.
It generates revenue by manufacturing and distributing agrochemical products through a B2B model to corporate clients. In FY25, total revenue was ₹502.26 crore. Formulation Grade products dominate sales, accounting for 98.99%, or ₹497.20 crore, of revenue.